DrugPatentWatch Database Preview
SYLATRON Drug Profile
» See Plans and Pricing
Summary for Tradename: SYLATRON
Patents: | 33 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 1 |
Recent Clinical Trials: | See clinical trials for SYLATRON |
Recent Clinical Trials for SYLATRON
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Merck Sharp & Dohme Corp. | Phase 2 |
Georgetown University | Phase 2 |
Roswell Park Cancer Institute | Phase 2 |
Pharmacology for SYLATRON
Ingredient-type | Interferon Alfa-2b Interferon-alpha |
Company Disclosures: US Patents for SYLATRON
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | Enzon, Inc. (Piscataway, NJ) | 2013-11-10 | RX | Orphan | company |
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | Enzon, Inc. (Piscataway, NJ) | 2013-11-10 | RX | Orphan | company |
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for SYLATRON
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) | 2031-04-05 | RX | Orphan | search |
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2029-05-13 | RX | Orphan | search |
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | 2040-03-24 | RX | Orphan | search | |
Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | ForSight Vision4, Inc. (South San Francisco, CA) | 2029-01-29 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for SYLATRON
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 0969866 | Start Trial |
European Patent Office | 2331134 | Start Trial |
Canada | 2734265 | Start Trial |
European Patent Office | 2332576 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |